Research programme: ghrelin antagonists - Ocera Therapeutics

Drug Profile

Research programme: ghrelin antagonists - Ocera Therapeutics

Alternative Names: TZP-301

Latest Information Update: 14 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tranzyme Pharma
  • Developer Deleted company 144
  • Class
  • Mechanism of Action Ghrelin antagonists; Ghrelin inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Metabolic syndrome; Obesity

Most Recent Events

  • 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
  • 04 Sep 2013 No development reported - Preclinical for Metabolic syndrome in USA (unspecified route)
  • 04 Sep 2013 No development reported - Preclinical for Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top